ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
BeOne Medicines Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$370.17+1.11 (+0.30%)
Close on Oct 19, 2026
- Market cap
- $557.24B
- P/E (TTM)
- 860.9
- Dividend yield
- –
BeOne Medicines Ltd. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $5.28B | $3.78B | $2.19B | $1.25B | $633.99M | $308.87M | $222.60M | $130.89M | $24.43M | $0 | 98.9% | +39.8% |
| Other revenue | $60.97M | $30.70M | $268.93M | $161.31M | $542.30M | $0 | $0 | $67.34M | $213.96M | $1.07M | 1.1% | +98.6% |
| Reimbursement of research and development costs | – | – | – | – | $0 | $0 | $27.63M | $56.78M | $0 | $0 | – | – |
| Research and development service revenue | – | – | – | $46.82M | $53.67M | $0 | $0 | $10.56M | $2.57M | $1.07M | – | – |
| License revenue | – | – | – | – | – | – | $0 | $0 | $211.39M | $0 | – | – |
| Other | – | – | – | $9.49M | $0 | $0 | $0 | $0 | $0 | – | – | – |
| License revenue | – | – | – | $0 | $484.65M | $0 | $0 | – | – | – | – | – |
| Right to access intellectual property revenue | – | – | – | $104.99M | $3.98M | $0 | $0 | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.88B | $1.96B | $1.13B | $502.63M | $495.27M | $18.23M | $134.69M | $42.79M | $138.42M | $0 | 53.9% | +47.1% |
| China | $1.68B | $1.41B | $1.10B | $840.03M | $517.10M | $290.65M | $221.56M | $132.39M | $24.43M | $0 | 31.4% | +19.0% |
| Europe - total revenue | $611.37M | $362.63M | $202.01M | $63.26M | $163.05M | – | – | – | – | – | 11.4% | +68.6% |
| Rest of world- total revenue | $171.81M | $78.81M | $26.60M | – | – | – | – | – | – | – | 3.2% | +118.0% |
| Rest of world - total revenue | – | $78.81M | $26.60M | $10.01M | $863.00K | $0 | $71.97M | $23.04M | $75.54M | $1.07M | – | – |
From the segment and revenue-disaggregation notes of BeOne Medicines's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.